Bone Biologics (BBLG) Stock Overview
A medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BBLG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Bone Biologics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.28 |
| 52 Week High | US$6.75 |
| 52 Week Low | US$1.05 |
| Beta | 0.37 |
| 1 Month Change | 4.92% |
| 3 Month Change | -17.42% |
| 1 Year Change | -68.10% |
| 3 Year Change | -99.64% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Shareholder Returns
| BBLG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.3% | 0.6% | 3.0% |
| 1Y | -68.1% | 41.7% | 25.7% |
Return vs Industry: BBLG underperformed the US Biotechs industry which returned 45% over the past year.
Return vs Market: BBLG underperformed the US Market which returned 32.8% over the past year.
Price Volatility
| BBLG volatility | |
|---|---|
| BBLG Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: BBLG has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BBLG's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 2 | Jeff Frelick | www.bonebiologics.com |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications.
Bone Biologics Corporation Fundamentals Summary
| BBLG fundamental statistics | |
|---|---|
| Market cap | US$2.22m |
| Earnings (TTM) | -US$3.11m |
| Revenue (TTM) | n/a |
Is BBLG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBLG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$3.11m |
| Earnings | -US$3.11m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BBLG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/08 14:56 |
| End of Day Share Price | 2026/04/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bone Biologics Corporation is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bradley Sorensen | Zacks Small-Cap Research |